maricla galetti
maricla galetti
Department of Clinical and Experimental Medicine
Verified email at
Cited by
Cited by
Everolimus restores gefitinib sensitivity in resistant non-small cell lung cancer cell lines
S La Monica, M Galetti, RR Alfieri, A Cavazzoni, A Ardizzoni, M Tiseo, ...
Biochemical pharmacology 78 (5), 460-468, 2009
Overcoming acquired resistance to letrozole by targeting the PI3K/AKT/mTOR pathway in breast cancer cell clones
A Cavazzoni, MA Bonelli, C Fumarola, S La Monica, K Airoud, R Bertoni, ...
Cancer letters 323 (1), 77-87, 2012
Glomerular autoimmune multicomponents of human lupus nephritis in vivo: α-enolase and annexin AI
M Bruschi, RA Sinico, G Moroni, F Pratesi, P Migliorini, M Galetti, C Murtas, ...
Journal of the American Society of Nephrology 25 (11), 2483-2498, 2014
Novel irreversible epidermal growth factor receptor inhibitors by chemical modulation of the cysteine-trap portion
C Carmi, A Cavazzoni, S Vezzosi, F Bordi, F Vacondio, C Silva, S Rivara, ...
Journal of medicinal chemistry 53 (5), 2038-2050, 2010
Dual mechanisms of action of the 5-benzylidene-hydantoin UPR1024 on lung cancer cell lines
A Cavazzoni, RR Alfieri, C Carmi, V Zuliani, M Galetti, C Fumarola, ...
Molecular Cancer Therapeutics 7 (2), 361-370, 2008
Effects of sorafenib on energy metabolism in breast cancer cells: role of AMPK–mTORC1 signaling
C Fumarola, C Caffarra, S La Monica, M Galetti, RR Alfieri, A Cavazzoni, ...
Breast cancer research and treatment 141 (1), 67-78, 2013
Trastuzumab emtansine is active on HER-2 overexpressing NSCLC cell lines and overcomes gefitinib resistance
D Cretella, F Saccani, F Quaini, C Frati, C Lagrasta, M Bonelli, C Caffarra, ...
Molecular cancer 13 (1), 143, 2014
5-Benzylidene-hydantoins: synthesis and antiproliferative activity on A549 lung cancer cell line
V Zuliani, C Carmi, M Rivara, M Fantini, A Lodola, F Vacondio, F Bordi, ...
European journal of medicinal chemistry 44 (9), 3471-3479, 2009
Sirolimus plus prednisone for Erdheim-Chester disease: an open-label trial
D Gianfreda, M Nicastro, M Galetti, F Alberici, D Corradi, G Becchi, ...
Blood, The Journal of the American Society of Hematology 126 (10), 1163-1171, 2015
Particle toxicology and health-where are we?
M Riediker, D Zink, W Kreyling, G Oberdörster, A Elder, U Graham, ...
Particle and fibre toxicology 16 (1), 19, 2019
Association of serum C3 concentration and histologic signs of thrombotic microangiopathy with outcomes among patients with ANCA-associated renal vasculitis
L Manenti, A Vaglio, E Gnappi, U Maggiore, L Allegri, M Allinovi, ...
Clinical Journal of the American Society of Nephrology 10 (12), 2143-2151, 2015
Effect of ABCG2/BCRP expression on efflux and uptake of gefitinib in NSCLC cell lines
M Galetti, PG Petronini, C Fumarola, D Cretella, S La Monica, M Bonelli, ...
PloS one 10 (11), e0141795, 2015
Metabolism of the EGFR tyrosin kinase inhibitor gefitinib by cytochrome P450 1A1 enzyme in EGFR-wild type non small cell lung cancer cell lines
RR Alfieri, M Galetti, S Tramonti, R Andreoli, P Mozzoni, A Cavazzoni, ...
Molecular cancer 10 (1), 1-14, 2011
Glomerular autoimmune multicomponents of human lupus nephritis in vivo (2): planted antigens
M Bruschi, M Galetti, RA Sinico, G Moroni, A Bonanni, A Radice, A Tincani, ...
Journal of the American Society of Nephrology 26 (8), 1905-1924, 2015
Gefitinib inhibits invasive phenotype and epithelial-mesenchymal transition in drug-resistant NSCLC cells with MET amplification
S La Monica, C Caffarra, F Saccani, E Galvani, M Galetti, C Fumarola, ...
PloS one 8 (10), e78656, 2013
Synergistic activity of letrozole and sorafenib on breast cancer cells
MA Bonelli, C Fumarola, RR Alfieri, S La Monica, A Cavazzoni, M Galetti, ...
Breast cancer research and treatment 124 (1), 79-88, 2010
Functional characterization of gefitinib uptake in non-small cell lung cancer cell lines
M Galetti, RR Alfieri, A Cavazzoni, S La Monica, M Bonelli, C Fumarola, ...
Biochemical pharmacology 80 (2), 179-187, 2010
Dose-dependent effect of FHIT-inducible expression in Calu-1 lung cancer cell line
A Cavazzoni, PG Petronini, M Galetti, L Roz, F Andriani, P Carbognani, ...
Oncogene 23 (52), 8439-8446, 2004
Epidermal growth factor receptor tyrosine kinase inhibitors: current status and future perspectives in the development of novel irreversible inhibitors for the treatment of …
E Galvani, R Alfieri, E Giovannetti, A Cavazzoni, S La Monica, M Galetti, ...
Current pharmaceutical design 19 (5), 818-832, 2013
Cytocompatibility and Cellular Internalization Mechanisms of SiC/SiO2 Nanowires
A Cacchioli, F Ravanetti, R Alinovi, S Pinelli, F Rossi, M Negri, E Bedogni, ...
Nano Letters 14 (8), 4368-4375, 2014
The system can't perform the operation now. Try again later.
Articles 1–20